Koji Mita
Overview
Explore the profile of Koji Mita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hatayama T, Mita K, Kohada Y, Fujiyama K, Tasaka R, Goriki A, et al.
Investig Clin Urol
. 2025 Mar;
66(2):144-151.
PMID: 40047128
Purpose: Scheduled administration of intravenous acetaminophen improves catheter-related bladder discomfort (CRBD) after urological surgery. However its efficacy for patients undergoing transurethral resection of bladder tumors (TURBT) remains unclear. This study...
2.
Tanaka N, Izumi K, Nakai Y, Shima T, Kato Y, Mita K, et al.
Prostate
. 2024 Sep;
85(1):21-29.
PMID: 39301921
Background: A head-to-head comparison between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) revealed similar survival benefits for castration-resistant prostate cancer (CRPC) in the ENABLE study for PCa. Considering that a...
3.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, et al.
J Immunol
. 2024 May;
213(1):23-28.
PMID: 38758119
Immune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual...
4.
Kobayashi K, Takahashi S, Yasuda M, Miyazaki J, Wada K, Matsumoto M, et al.
J Infect Chemother
. 2024 Apr;
30(7):579-589.
PMID: 38588797
Introduction: Antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using the national surveillance data, comprising 793 bacterial strains from eight clinically relevant...
5.
Hatayama T, Goto K, Fujiyama K, Goriki A, Kaneko M, Mita K
Asia Pac J Clin Oncol
. 2024 Mar;
21(2):156-162.
PMID: 38512888
Aim: This study aimed to evaluate the risk classification system using the detailed positive surgical margin (PSM) status to predict biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP). Methods: We...
6.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339260
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear....
7.
Teishima J, Murata D, Yukihiro K, Sekino Y, Inoue S, Hayashi T, et al.
Curr Urol
. 2023 Sep;
17(1):52-57.
PMID: 37692134
Objectives: This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma. Marterials And Methods: Fifty-eight patients with metastatic renal...
8.
Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, et al.
Int J Urol
. 2023 Aug;
30(9):788-796.
PMID: 37528632
Background: This study is part of the SNPs in Nivolumab PD-1 inhibitor for RCC (SNiP-RCC). Here we aimed to reveal clinical factors for tumor response, progression, and survival in nivolumab...
9.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, et al.
Cancer Immunol Immunother
. 2023 Feb;
72(6):1903-1915.
PMID: 36729213
Background: Anti-PD-1 antibodies are widely used for cancer treatment including advanced renal cell carcinoma (RCC). However, their therapeutic and adverse effects vary among patients. This study aimed to identify genetic...
10.
Takemoto K, Sekino Y, Kitano H, Ikeda K, Goto K, Hieda K, et al.
Int J Urol
. 2022 Nov;
30(3):319-327.
PMID: 36448526
Objective: To evaluate the significance of both low and high body mass index (BMI) as a biomarker in first-line tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). Methods:...